IQVIA Holdings has recently seen its consensus analyst price target rise significantly, climbing from $223.42 to $246.84.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci ...

On November 5, 2025, IQVIA Holdings Inc. announced the appointment of Dr. William G. Kaelin Jr. to its Board of Directors. Dr. Kaelin, a Nobel Prize-winning scientist with extensive expertise in ...

IQVIA's third quarter results reflected stable operational execution, with revenue and profit slightly ahead of Wall Street expectations. Management identified robust free cash flow generation and a ...

Oakmark spotlights six stocks driving AI, M&A, and analytics upside, while navigating debt, guidance cuts, and valuation ...

Oakmark highlights M&A upside, AI tailwinds, and valuation disconnects across key holdings. See why bottom-up conviction ...

Ibnsina Pharma ranked first in non-pharma product distribution across pharmacies in Egypt during the first nine months of ...

Discover three strategies for MedTech companies to design streamlined, effective trials and how quality data powers smarter ...

Wordwide IoT antenna shipments are projected to recover to 13 billion units by 2030, according to global technology intelligence firm ABI Research. While lingering post-pandemic effects and ...

Two major themes cut across the week’s news: the profound integration of advanced technology, particularly Artificial ...